Therapeutic Advances in Major NBIA Disorders: Current Strategies and Translational Challenges.
Iron-reducing drugs and experimental gene therapies show promise for rare genetic brain disorders, though ultra-small patient populations and disease variability hinder definitive progress.
This review synthesizes therapeutic progress across major neurodegeneration with brain iron accumulation (NBIA) subtypes—PKAN, MPAN, BPAN, and PLA2G6-associated neurodegeneration—covering iron chelation (deferiprone in PKAN), coenzyme A precursor supplementation, antioxidants, and emerging gene therapy. Despite preclinical promise, translational challenges including disease heterogeneity, lack of validated biomarkers, and ultra-small patient populations (often <200 known cases per subtype) have impeded definitive clinical progress.
What the study was
- Study design
- narrative_review
- Population
- Patients with major NBIA subtypes (PKAN, MPAN, BPAN, PLA2G6-associated neurodegeneration)
- Category
- Drug Development
- Maturity
- Exploratory
- Journal
- Neurol Int
Why it surfaced
Comprehensive review (Neurol Int) of the therapeutic landscape for NBIA disorders—a group of ultra-rare neurodegenerative diseases with high unmet need and no approved curative treatments—providing a useful pipeline tracking overview of gene therapy and small-molecule approaches in this space.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.